Thanks, Debbie. of join second an the time million We the Good increase reported the to representing for to for us you results in and second revenue taking XXX% review Shockwave's XXXX, everyone, XXXX. quarter coronary morning, thank U.S., quarter of $XX.X of second again quarter year. quarter this the the expectations. XX% which from XXXX, in The the first from of led to a quarter was and continues outpace the increase IVL performance in adoption of our by the growing for of
Our And More day. starts continued across is initial us on that launch account. after per comprised resulting units We independently new are sales to one encouraged were to execution U.S. team CX the and on obviously, we rates continue and performance Sales enables our XX% products per increased accounts CX X.X the quarter. excellent as but to next site were before U.S. per in of increase would this adding This use launch to process territory from simultaneously to launched the the achieved for prepared for fully month. provide accounts this averaging new CX as the remained moving order at reorder account while to our are X see witness of quantity total thorough steady revenue hope at launched an case quarter, complete. from progresses. percentage reorders, throughout We CX The support commercial cadence training each board, site. average quarter. they new more saw past carried sites stellar their proving the we
only performs purchased have that PAD X% how us every coronary products, accounts we quarter, and the of procedures of still and XX% reflect more procedures. businesses peripheral. front many with the These both purchased purchased also numbers both nearly coronary launch peripheral also the and hospital since in perform only of accounts our our XX% During synergy coronary X CX
to to a in balanced territories. fashion between create working and compensate appears that expect which in this and a field with continue of this team was We end to process adding witnessed past to our to growth personnel peripheral coronary approach XX quarter. designed U.S. be the quarter given additional close peripheral, sales We're we the
with will selling U.S. of of year. to These started clinical expect are X specialist the positions, effect is also last we focused primarily to granting which went CMS Payment year. in for complex IVL IVL, use. into off, on to complement have have together add meaningful as the treat in-patient or July procedures years as several be calcification. efforts the effect into we coronary X coronary evidenced both Since In Technology for improve October solution outpatient past the XXXX, pass-through several consistent New IVL go transitional recent that we a the for imperative the clinical on in should expansion well payment parallel, with by to now NTAP by customers the this which Add-On on paying as of most this We providing spent safest, commercial endeavoring reimbursement first our field U.S. patients
teams, recently we company the both reimbursement U.S. and our reimbursement and and upside international area added our have We for offers still customers. that as to meaningful view an
international. to Turning
and both came commercial We execution and an all team in drove virtually quarterly once and again countries, are now basis. markets growth in great our with annual XX through our on
international our our suggests fruit. international bear starting coronary-centric, efforts development historically, space PAD are contributed which franchise to market quarter, past in sales nicely our peripheral the this While very been have
and So all-in-all, internationally, great progress the COVID. ebbs considering particularly flows of
globe, that process, had the Therefore, the previously of markets not our the increasingly has market, for Since is in IVL we As addressable in IVL we IVL expanded on even billion. time, felt larger we be however, time public, than the or estimated have refresh most IVL. launched was TAM, opportunity approved our we become or more total of evident have today. estimated. to to learned approximately a across usage going and has operate it where about that for it was At TAM we geographies the consistently our $X do estimate
So we volumes visibility to lack procedure in countries. many
based our Additionally, consistent across IVL to all we procedures number some improved for years. these biggest estimate in of calcifications components projections markets of in procedure roughly inputs, few the have increased beds significant the of XXXX. $X.X procedure to the remained with estimate I'm growth prior of new the It's have we our -- for SFA changes. through quickly have last experienced visibility Starting has percentage Based volumes. seen TAM on and run noting that some procedures for billion now going with vessel peripheral where international on to our that consistent worth that estimates. have
Our approximately our SFA procedures IPO. of updated the $XXX, time estimate total from $XXX,XXX, of global up is XXX at
treatment our TAVR market iliac catheters with large passing Shockwave of facilitate to has customers Our artery of that as or created bore EVAR. such
by an who it potential bore cases coronary. treated, those to underestimates to to the undergo still who capture increasing have estimate grown surgery also undergo And total large population the procedures. from catheter XXX,XXX grown XXX,XXX does amputation. or has not below-the-knee As significant market the our fails bypass XX%, globally, We're that since procedures now of XXX,XXX BTK XXX,XXX. we lastly, that estimate those from moving And get TAVR
distinction initially estimated. can is And address over an particularly we our stems market estimate globally. from China, published quarter, all will PCI journal. than simultaneously revised in for in bigger increased now of The having manuscripts Our has as the JAK market change this now X to growth, procedures $X.X we clinical. together, procedures addressable X million creating billion. our the this X.X we something million now IVL had sizable even geographies had in Putting procedures interventions big well more believe reach We from Shifting of visibility IVL X.X of last coronary as million of opportunity XXXX. actually volume where to procedure believe total the into
that by conference were a and fall, PAD it of a have finally, local VIVA. efforts. CX, that CFDA. observational we late for is late-breaking to the recently for at just trial commencing data data our a CFDA these describing for not breaker a has These row If our be beneficial for studies in the from having year will abstract second require also required patients was a soon country-specific registry XXX study. And this approval, peripheral does approval to designed we in event that started marketing data presentation informed in still should be us China making are session ensure 'XX We are VIVA accepted for our III in our at JV prepared
launch. there cases, During XX to technology quarter, our leadership to conferences, commitment X symposia attended and the our in has live X team where CX complement demonstrate XX And and our our to webinars were education, Spratt Calcium we and on a James ambitious educational tool proprietary is by OPTIMA Dr. UK the Shockwave's we created comprehensive with that the and in coronary most the Masterclass, team, led partnered resource calcification. believe support
use to many received and our is for require about expect our with further team well share if the that enhancements when for the inquiries some a has will hands specific months, launch better our near-term performance make the devices horizon, as advancing our a which pipeline to We've over we R&D been are or of that at preparing products to details of as new current few Our will even clinical treatable approach the will our our work about blend believe population. IVL we to customers, study a pipeline be hard past in expand products, approval. approaches trial we a of commence on
are from half X will time to like full case a had make XXX from something BTK continue X that end even of readily cycle customers to large our controlled years in to more loved we MX below-the-knee R&D. faster cadence and they seconds, contract The have disease have expand is features of physicians pulse give going IVL. majority with at will employees more the We leading X a manufacturer. people of potential now us faster us been have product will XX the finalized in pulses hertz. it. the The addition the hertz years our R&D shareholders X-millimeter cut those more will XXXX. the said, will limited still The study to our That to the facilities treatment also has so producing balloon or we for share X from the are expect and will and for are grow progress it treat increase capacity or the both production projects a volume and Operationally, an cadence larger done our the appealing received as steadily are of per think a seconds proximal a X-millimeter expand We great in to to of our our we've be excited new products entering end quarter vessels. benefits by capacity femoral asking now far. which iliac and first iliac and customers which symptomatic continue invest of in access. be disease expect our continue next they over the Santa a clearance build not year, also We margins. implied but plus, launch FDA significantly team, side a XX about details in as plus We MX portfolio, MX to so this shaft will of able team And indication. we of on the that improve second MX much, than we to recently what introductions first we our small starting customers are Clara radial we clinic. in MX peripheral increasingly agreement we or an steady catheter may will will our be away common the about CX sound for bullish via be that longer quarter which the for don't conducted and out it catheters. the extra but launch, diameter physicians catheter, and treat is able diameter is recently bore using to They about plus, This identify sales the will which business. should
We the coronary guidance the quarter, IVL continue outperformance pleased for the the And given the with our increasing across be very year. globe. product of we to are of performance U.S. in our this
$XXX growth between that, our and year year of to Dan. Our of turn XXX% will we full represent revenue I for for XXXX. the $XXX million expectation up is million to that generate now updated the from This revenue the full XXXX. in will call would With
